Dr Jacob Adashek speaks about the current and future landscapes of PARP inhibitors in the treatment of prostate cancer.

Dr Adashek speaks about which drugs are currently approved and the significance of identifying which patients could benefit from these treatments.

He comments on some relevant ongoing trials and gives insights on his own clinical experience.

Dr Adashek concludes by discussing how PARP inhibitors might be used to treat prostate cancer in the future, explaining why he thinks a combination approach with hormone deprivation therapy is a promising direction.

This programme has been supported by an unrestricted educational grant from Pfizer.